The Future Of Medicine: Cell And Gene Therapies Take The Lead
BY MANDY JACKSON Executive Summary BIO panel with Roche’s James Sabry, Spark’s Federico Mingozzi and Adaptive’s Harlan Robins imagines a world where cell and gene therapies are preferred over small molecules and antibodies.
15 / August 2020
Gene therapies that program the body to make therapeutic antibodies, genetic surgery that replaces anatomical surgery and cell therapies designed to attack individual cancer patients’ tumors almost sound like science fiction, but in the eyes of Roche global partnering head James Sabry those types of innovations are the not-so-distant future of medicine. Sabry, Spark Therapeutics Inc. chief scientific officer Federico Mingozzi and Harlan Robins, Adaptive Biotechnologies Corp. chief scientific officer and co-founder, discussed the future of regenerative medicines during an 8 June discussion of “Next-Generation Medicine: Cell and Gene Therapies and Beyond” as part of the Biotechnology Innovation Organization’s annual international meeting taking place 8-12 June online. Novel cell and gene therapies require risk-taking and partnership to move the field forward, the executives agreed.
© Informa UK Ltd 2020 (Unauthorized photocopying prohibited.)
